trial · primary record
NX-5948
Chronic Lymphocytic Leukemia (CLL)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2030-10 |
| Primary endpoint | Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC) |
| Registry ID | NCT07221500 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:51.315Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07221500
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Nx-5948 · compound